-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AGI-134 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AGI-134 in Solid Tumor Drug Details: AGI-134 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PHE-885 in Refractory Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PHE-885 in Refractory Multiple Myeloma Drug Details:PHE-885 is under development for the treatment of relapsed and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GN-037 in Plaque Psoriasis (Psoriasis Vulgaris)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GN-037 in Plaque Psoriasis (Psoriasis Vulgaris) Drug Details: GN-037 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Telitacicept in IgA Nephropathy (Berger’s Disease)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Telitacicept in IgA Nephropathy (Berger's Disease) Drug Details: Telitacicept (Tai' ai) is a potential new...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Telitacicept in Antiphospholipid Syndrome
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Telitacicept in Antiphospholipid SyndromeDrug Details:Telitacicept (Tai' ai) is a potential new TACI-Fc fusion protein, acts as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Telitacicept in Systemic Lupus Erythematosus
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Telitacicept in Systemic Lupus Erythematosus Drug Details: Telitacicept (Tai' ai) is a potential new TACI-Fc...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Telitacicept in Relapsing Remitting Multiple Sclerosis (RRMS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Telitacicept in Relapsing Remitting Multiple Sclerosis (RRMS) Drug Details:Telitacicept (Tai' ai) is a potential new TACI-Fc...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Iodine I 131 Apamistamab in Diffuse Large B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Iodine I 131 Apamistamab in Diffuse Large B-Cell Lymphoma Drug Details: Iomab-B, a radioimmunoconjugate (BC8-I-131...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Aflibercept in Graves’ Ophthalmopathy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Aflibercept in Graves' Ophthalmopathy Drug Details: Aflibercept (Eylea / Eylea HD) is a recombinant fusion...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Disitamab Vedotin in Salivary Gland Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Disitamab Vedotin in Salivary Gland Cancer Drug Details: Disitamab vedotin (Aidexi) is an antibody-conjugated drug...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.